Lilly’s Ramucirumab Fails In Breast Cancer Trial, Clears Second Gastric Cancer Study
This article was originally published in The Pink Sheet Daily
Lilly’s VEGF2-inhibitor failed to meet its primary endpoint of progression-free survival in a Phase III breast cancer study but met the primary endpoint of improved overall survival in an advanced gastric cancer trial.
You may also be interested in...
Lilly’s necitumumab – gained through the company’s ImClone acquisition – demonstrates an overall survival benefit in the SQUIRE study against first-line metastatic squamous NSCLC. Pleasantly surprised by the outcome, some analysts start to expect blockbuster sales.
The vascular endothelial growth factor inhibitor demonstrated a 1.4 month improvement in overall survival, giving some investors the jitters but encouraging clinician experts, especially given previous targeted drug trial failures.
Enrollment-boosting strategy backed by industry rep at Duke-Margolis meeting as FDA official suggests having sponsors develop study plans for pregnant and lactating women with ‘elements of’ the requirement for pediatric studies.